Enrollment Complete in Tumor-HI Pivotal; Topline Set for Mid-December 2026

What happened

Rezolute has completed enrollment in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with topline data expected in mid-December 2026. This milestone keeps the only remaining registrational program on track after the December 2025 sunRIZE failure in congenital HI. The open-label, single-arm design with approximately 16 patients was pre-agreed with the FDA and uses objective inpatient glucose-infusion-rate endpoints, though it carries inherent statistical and regulatory risk. While this operational update is mildly positive, it does not alter the fundamental binary nature of the asset or the company’s ~$168 million cash runway. The stock remains a speculative wager on a single late-stage readout, with no near-term revenue or additional pipeline support.

Implication

Completion of upLIFT enrollment confirms operational execution but offers no incremental evidence of efficacy or probability-of-success improvement. Investors should continue to treat Rezolute as a binary, single-asset biotech with a failed congenital trial and an unblinded, small-N tumor-HI study. The topline in December will be the dominant catalyst; until then, price movements will likely reflect sentiment, litigation headlines, and cash-burn updates rather than fundamentals. A positive result could justify a re-rating toward $4–6, while failure would likely compress the stock toward cash-per-share levels. Given the existing litigation overhang and lack of a margin of safety beyond cash, capital is better preserved until data or deeper FDA feedback provides asymmetric upside.

Thesis delta

Enrollment completion in upLIFT is a mild positive that removes a previously identified execution risk but does not change the base-case valuation or the binary profile of the company. The thesis shifts slightly from “awaiting confirmation that the streamlined trial can enroll” to “confirmed enrollment but awaiting unblinded data,” which increases operational confidence without altering probability-weighted outcomes. The WAIT rating and $2.00 attractive entry remain intact, as the stock still lacks a clear risk-reward edge at current prices.